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ABSTRACT
Tasosa, Joseph T., M.B.A., Department of Social and Applied Economics, Wright State 
University, Dayton OH, 2004.
A Comparative Evaluation of the Cost Effectiveness of Treating the Metabolic Syndrome 
in African Americans and the General Population1
•The Metabolic Syndrome poses an important public health threat to the U.S. health care 
delivery system. Disparate access to quality health care makes African Americans 
(blacks) especially susceptible to the adverse effects of MS. Although direct evidence 
suggests that early treatment of MS risk factors saves lives, no study to date has 
compared the cost effectiveness of such measures in blacks and the general population. 
Interventions that promote early treatment of MS risk factors may improve public health 
but could also lead to excess costs that are ultimately borne by society. The objective of 
this study was to assess the value of early treatment of MS risk factors in blacks and the 
general population. A cost effectiveness analysis was carried out using a Markov decision 
model to compare early treatment and late treatment of MS risk factors in blacks and the 
general population. The main outcome measure was the incremental cost per Quality 
Adjusted Life Year (QALY). With the exception of early treatment of hyperlipidemia in 
blacks ($ 187,462/QALY), early treatment of individual MS risk factors at age 30 was 
found to be cost effective (<$27,000/QALY) for both blacks and the general population. 
With the exception of treatment of hyperlipidemia, early treatment strategies targeted at 
blacks were found to be more cost effective than those targeted towards the general 
population. Sensitivity analyses indicated that age and cost of treatment were the most 
influential factors in the model. The cost effectiveness of early treatment of MS risk 
factors in blacks and the general population compares favorably with similar health care 
interventions. The results support a growing body of literature that indicates the cost 
effectiveness of providing preventative services to apparently healthy individuals.
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The Metabolic Syndrome (MS) is a group of risk factors 
that are known to increase the incidence of cardiovascular 
and renal disease. These risk factors include abdominal 
obesity, insulin resistance, hypertension and dyslipidemia 
(Appendix A). The impairment of the fibrinolitic system 
and the presence of prothrombic and proinflammatory states 
have also been cited as important components of MS.
The National Health and Nutrition Examination Survey 
III (NHANES III, 1988-94) found 25% of all U.S. adults and 
42% of those over the age of 60 have MS (Ford et al, 2002). 
Despite the high prevalence, there is still no generally 
accepted definition of MS (Scott, 2003). Most experts 
however, agree that the simultaneous presentation of three 
of the four major risk factors is sufficient for defining 
the MS (National Cholesterol Education Program Adult 
Treatment Panel III 2001 [NCEP ATP III], Meigs, 2002). For 
a more detailed discussion on the history and issues 
surrounding the definition of MS, see Appendix B.
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Racial Disparities in Health care
Racial disparities in health care are described as 
"...racial or ethnic differences in the quality of health 
care that are not due to access related factors, clinical 
needs, preference, or appropriateness of intervention 
(Smedley et al [eds], 2003)." The Institute of Medicine 
(2003) views racial disparities in the context of the legal 
and regulatory climate of health care systems and in the 
context of stereotyping and prejudice.
As cited by Williams and Collins (1994), disparities 
in the provision of health care tend to diminish when 
socio-economic factors are held constant. Kitagawa and 
Hauser (1973) support this idea by documenting diminishing 
returns to health beyond a certain level of income. 
Similarly House et al (1993) conclude that income related 
health gains diminish for household incomes above $20,000 
per year.
While these assertions may be true for access related 
issues, Kressin and Petterson (2001) and Ofili (2000) argue
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that racial disparities remain even after an adjustment for 
socio-economic status and other health care access related 
factors are accounted for.
The extent of health disparities in the African 
American (black) community has been extensively chronicled. 
Such documentation indicates race as an important factor in 
the diagnosis of MS risk factors. Blacks, for example, have 
a reduced chance of being diagnosed of some risk factors 
and therefore have a higher risk of cardiovascular disease 
than do whites (Brancati et al, 2000; Karter et al, 2002). 
As cited by Bell et al (2004), blacks are 1.97 times more 
likely to have untreated hypertension than are whites even 
after adjusting for socio-economic status.
Although racial and ethnic disparities in health care 
are consistent across a wide range of diseases and health 
care services (IOM, 2003), this study will focus on racial 
disparities as they relate to the MS. The purpose of this 
project is to study the economic cost of treating MS risk 
factors in blacks versus the general population.
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General Population
New standards were announced in 1997 for the 
classification of individuals by race within the U.S. 
Federal Government's national data systems (Freid et al,
2003). These standards classified individuals under five 
main racial groups: American Indian or Alaska Native,
Asian, Black or African American, Native Hawaiian or 
Pacific Islander and White. Race and Hispanic origin are 
considered as two separate and distinct concepts, thus 
Hispanics may be of any race. The general population in 
this study contains individuals from all five racial 
groups.
The purpose of this project is to study the economic 
cost of treating MS risk factors in blacks versus the 
general population at the national level thus national data 
was used. National data was also used because it is the 
most consistent and the most available.
Societal Perspective of Cost Effectiveness Analysis
Cost effectiveness analysis (CEA) is used by health 
consumers to assess the relative value of different health 
care services and by the health care industry to support
4
marketing claims. CEA is particularly useful when policy 
makers seek efficient policies but face certain constraints 
that prevent them from doing the more traditional Cost 
Benefit Analysis (Boardman et al, 2001). These constraints 
include the inability to capture all the social costs of an 
intervention (Gold et al, 1996). Social costs in our study 
measure the loss of economic productivity associated with 
MS outcomes.
Despite the importance, the loss of economic 
productivity was not factored into our CEA because it is 
difficult to quantify and could not be easily incorporated 
into our model. The QALY our measure of effectiveness has 
also been accused of not measuring social value because its 
preferences and weights are based on an individualistic 
perspective rather than a societal perspective (Drummond et 
al, 2000). Since it is society that ultimately bears the 
cost of health care, it would seem more appropriate if a 
more socially sensitive unit is used to measure cost and 
effectiveness. When all social costs are captured, the 




Treatment Options and Clinical Outcomes
The progression path of the Metabolic Syndrome is 
illustrated through a Markov decision tree diagram (Fig. 1A 
and Fig. IB) constructed using DATA 4.0 (TreeAge Software, 
Inc., Williamstown MA, USA). The model is able to simulate 
possible disease progression pathways by tracking a 
theoretical group of blacks and another of the general 
population at risk of the MS.
At the end of the simulation, the model calculates the 
number of people alive under each pathway and the costs 
involved. The Markov model is also able to estimate 
quality of life under each treatment option and the cost 
effectiveness per Quality Adjusted Life Year (QALY) gained 
(see Appendix B) as the groups move from one transition 
state to another.
Two treatment options were identified, (1) early 
treatment and (2) late treatment. We assume that MS risk
6
factors in the late treatment option go untreated until a 
major clinical outcome occurs. This is often the status 
quo. Stroke, Myocardial Infarction (heart attack) and End- 
Stage Renal Disease (ESRD) were chosen as the three major 
clinical outcomes of MS because they can be easily 
measured, they are the most prevalent and they are the most 
sensitive to intervention.
The impact of Stroke, Myocardial Infarction (MI) and 
ESRD can be reduced by early detection and treatment of the 
major components of MS (Lakka et al, 2003; Berg et al,
2001). Our hypothesis assumes that we can drastically 
reduce the negative impact of MS outcomes in blacks and the 
general population if we are able to provide early and 
aggressive treatment. This is especially important in the 
context of eliminating racial disparities in health care 
because reducing the negative impact of MS outcomes in 
blacks may lead to a reduction in racial disparities in 
health care.
7
Fig 1A: Markov Decision Tree—African American
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Fig IBs Markov Decision Tree—General Population
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Although the economic costs of providing early 
treatment are high, these costs may be offset by increased 
productivity and increased quality of life that arise from 
early treatment. In this study, the economic impact of 
treating MS risk factors in blacks is compared to that of 
treating the MS in the general population.
Subgroup Analysis
A target population may be separated into specific 
subgroups that are expected to exhibit a different level of 
effectiveness due to the intervention. Blacks are selected 
as a subgroup of the general population because they have 
different incidence and mortality rates. Although subgroup 
analysis may be relevant to the decision maker, its 
relevance must be weighed against the decreased precision 
of available data (Gold et al, 1996). Blacks are chosen as 
a subgroup because data on them is more readily available 
compared to other racial minorities.
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Markov State Transition Model
Since some diseases and treatments are characterized 
by repetitive events, it becomes difficult for an analyst 
to portray this dynamic process in a static way (Drummond 
et al, 2000). The ability of the Markov model to represent 
repetitive events and its ability to accommodate the time 
dependence of both probabilities and utilities, allows it 
to more accurately represent clinical settings.
Markov models make the assumption that a patient is 
always in one of a finite number of health states also 
called Markov states. Events are represented as 
transitions from one Markov state to the other.
Markov models are useful when the timing of 
significant events is important and when these events are 
likely to happen more than once. Conventional decision 
trees are unable to accurately represent such clinical 
settings without over-simplifying model assumptions 
(Sonnenberg and Beck, 1993) .
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M arkov H ea lth , S t a t e s
Individuals in a cohort fall into one of the following 
definitive Markov states: (1) Well (2) Mild stroke, (3)
Severe stroke, (4) Fatal stroke, (5) Non Fatal MI, (6)
Fatal MI, (7) ESRD, (8) Disability and (9) Death.
The model is used to calculate the proportion of the 
cohort in each of the nine health states. The Markov model 
has a cycle time (the average amount of time spent in a 
health state) of one year and can only account for one 
transition between health states per year. A cycle time of 
one year is clinically meaningful even for rare events 
(Sonnenberg and Beck, 1993) but it can be shortened for 
more frequent events or for events that change rapidly 
(Goldman, 1983).
The model allows for persons to move from one state to 
another based on the transition probabilities of the two 
possible pathways. Transition probabilities help simulate 
the progression of groups through all possible combinations 
of events and outcomes over time. The type of event, the 
severity of the event and the age of an individual all 
influence the transition probabilities (Elliot et al,
12
2000). The severity of the event is in turn dependent upon 
a predetermined ratio of all possible outcomes of this 
event.
Individuals at the start of the simulation are assumed 
to be well. Individuals who recover completely can move 
back into the "well" state but individuals who become 
disabled or develop ESRD do not recover completely as these 
disease states are not regressive. A person in the well or 
disabled state may make a transition to the terminal death 
state. The death state (absorbing state) is the only state 
that a patient cannot leave. All the other states are 
temporary (See Fig. 2).
13
Fig. 2: Markov State Diagram. Each circle indicates a 
Markov state. Arrows indicate allowed transitions.
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Medical Costs
Only intensive treatment costs of hypertension, 
hyperlipidemia and diabetes are used as these have the best 
effect in improving health. Costs are based on studies 
done by the CDC Diabetes Cost Effectiveness Group (1998,
2002) and expressed in 2004 US dollars discounted at an 
annual rate of 3% per year. A 3% social discount rate is 
based on recommendations by the US Public Health Service 
Panel on Cost-Effectiveness in Health and Medicine (Gold et 
al, 1996: pp 233), on standard practice in economic 
evaluation (Weinstein and Stason, 1977; Brouwer and van 
Exel, 2004) and on related CEA studies (Busbee et al, 2003; 
Arguedas et al, 2004; Hoeger et al, 2004).
Costs of treating events are obtained from Elliot et 
al (2000). All costs are adjusted for inflation based on 
US Bureau of Labor Statistics inflation calculator and are 
listed in Table 1.
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Table Is Annual Costs of adverse events and treatment for 
30 year old
Variable Annual '
Cost of Disability $49,181
Cost of ESRD $42,461
Cost of Fatal Myocardial Infarction $19,097
Cost of Fatal Stroke $28,354
Cost of Mild Stroke $14,172
Cost of Non fatal Myocardial Infarction $38,215
Cost of Non fatal Stroke $56,750
Cost of Hyperlipidemia Treatment $ 1,638
Cost of Diabetes Treatment $ 1,228
Cost of Hypertension Treatment $ 701
1 Elliot et al (2000)
2 CDC Diabetes Cost-effectiveness Group
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Prevalence Rates and Mortality Rates
The annual age related incidence of Stroke, MI, and 
ESRD are obtained from studies done by Williams (2001),
U.S. Renal Data System (2003) and Wolf et al (1992) and are 
applicable to the general population.
Age specific mortality rates for the general 
population were estimated using 2000 U.S. life tables 
(Freid, et al, 2003) and these varied by race. As cited by 
(IOM, 2003) blacks have a 78% greater risk of mortality 
than the general population. Our assumption is that the 
excess mortality due to racial disparities in the provision 
of health care is 78% higher than that of the general 
population. Research also found the mortality rate of 
individuals with the MS to be twice as great as that of the 
average age, sex and race (ASR) adjusted mortality rate 
(Golan et al, 1999). These assumptions were incorporated 
into the life tables to estimate the impact of MS risk 
factors on mortality.
The adjusted hazard ratios for blacks (relative to 
that of whites) were 2.03 for ESRD (Karter et al, 2002) and
17
1.40 for Stroke (Pfizer, 2003). These hazard ratios were 
used to estimate the excess prevalence of ESRD and Stroke 
in blacks and the excess mortality in blacks due to ESRD 
and Stroke. Disability rates were derived from the US 
Social Security Database.
Although individuals with ESRD or disability are at an 
increased risk of having another event such as stroke or MI 
(Reaven et al, 1996), these effects have not been factored 
into the model, as literature on the event probabilities of 
such scenarios is not conclusive. We also know that 
individuals with multiple risk factors are at an increased 
risk of death than those without (Elliot et al, 2000). The 
synergistic effects of having multiple risk factors have 
however not been factored into the model.
Health utilities
Health utilities are cardinal values that enable 
researchers to measure health related quality of life under 
conditions of uncertainty. Health utilities provide a 
means to quantitatively measure and compare two health 
states. The standard gamble approach, the time trade-off
18
approach, rating scales and the willingness to pay approach 
are some of the methods used to calculate health utilities 
(Petrou, 2003). For a brief discussion on the standard 
gamble approach see Appendix D.
Defining a set of health states is the first step in 
measuring health utilities. Each health state is assigned 
a utility value between 0 and 1 whose endpoints are death 
and perfect health. Our study uses utility values developed 
by Rizzo et al (1998) and CDC Diabetes Cost effectiveness 
Group (2002). Stroke is assigned a value of 0.5, MI 0.88, 
ESRD 0.61 and disability 0.46. These utility values are 
then used to estimate QALYs. Since health utilities are 
relative values, we can assume that they are affected by 
age, sex, culture, socio-economic status and race. The 
utility values used in this analysis however, are not race 
specific because such data is unavailable.
With the use of transition probabilities and utility 
of life measures associated with each treatment option, the 
model calculates the cost effectiveness of early treatment 
of MS in blacks and the general population. The simulation 
automatically terminates when individuals turn 77 or die.
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Seventy-seven years is the life expectancy in the U.S. At 
the end of the simulation a group of 30 year olds was used 
as the base case to estimate parameters for both blacks and 
the general population.
Results
Base Case Analysis 
Blacks
The incremental cost per QALY is the additional costs 
that early treatment imposes over late treatment for each 
QALY gained (status quo). Early treatment of hypertension, 
hyperlipidemia and diabetes together in 30-year-old blacks 
came at an estimated incremental cost of $53,140/QALY 
gained. Early treatment of hyperlipidemia alone came at an 
estimated incremental cost of $187,462/QALY gained, while 
early treatment of diabetes alone and hypertension alone 
came at an incremental cost of $11,755 and $2,456 per QALY 
gained respectively (Table 2A).
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Table 2A: Cost/QALY Blacks
Age All Three Hyperlipidemia Diabetes Hypertension
20 78,816 121,393 19,939 7, 612
30 53,140 187,462 11,755 2, 456
40 36,363 517,696 5, 396 * *
50 23,259 * 224 * *
60 14,840 ★ * * * *
70 11,879 316,337 k k * k
* Late treatment dominated early treatment 
** Early treatment dominated late treatment
Dominance
When choosing between two alternatives, we first apply 
the principle of strong dominance. One program is said to 
dominate another if its effectiveness were higher and its 
costs lower. In this case it is unnecessary to calculate a 
cost-effectiveness ratio (Gold et al, 196). As shown in 
Table 2A late treatment of hyperlipidemia in blacks 
dominated early treatment at age 50 and 60. The additional
21
cost of early treatment of hyperlipidemia is not met with 
any additional improvement in the quality of life of blacks 
at this age. It is therefore more cost effective to 
maintain the status quo and not to employ any early 
treatment strategies targeted towards blacks in this age 
group. Early treatment of diabetes in blacks dominated 
late treatment at age 60 and 70 and early treatment of 
hypertension dominated late treatment in blacks over the 
age of 40.
General population
Early treatment of hypertension, hyperlipidemia and 
diabetes together in a 30-year-old member of the general 
population came at an estimated incremental cost of 
$63,926/QALY gained. Early treatment of hyperlipidemia 
alone came at an estimated incremental cost of $26,243/QALY 
gained, while early treatment of diabetes alone and 
hypertension alone came at an incremental cost of $17,789 
and $6,290 per QALY gained respectively (Table 2B).
With the exception of hyperlipidemia, the incremental 
cost per QALY gained by early treatment of MS risk factors 
was lower in blacks than it was in the general population. 
In general, this evidence suggests that early treatment of
22
MS risk factors in blacks is more cost effective than it is
for the general population. Since we assume that blacks are
more prone to the effects of MS than the general 
population, it follows that each additional dollar spent on 
preventative treatment of diabetes and hypertension in 
blacks saves more lives than each additional dollar spent 
on treating the same risk factors in the general
population. The high cost of aggressive treatment of
hyperlipidemia in blacks and the relatively low impact of 
this treatment however, makes it cost-ineffective relative 
to the general population.
Table 2Bs Cost/QALY General Population
Age All Three Hyperlipidemia Diabetes Hypertension
20 94,414 39,168 27,599 12,355
30 63, 926 26,243 17,789 6, 290
40 41,084 16,291 10,240 * *
50 25,412 8, 852 4, 602 * *
60 16,662 4, 641 1, 741 * *
70 14,213 4, 059 2, 051 * *
** Early treatment dominated late treatment
23
When early treatment is more effective but less costly 
than late treatment, it is said to dominate. In our results 
early treatment of hypertension is dominant over late 
treatment for individuals over 40 (Table 2B). Individual 
over 50 are the most prone to MS outcomes and so benefit 
the most from early treatment. Treating hypertension early 
may avoid the costly health problems it may cause if left 
untreated. As cited by the US Preventative Services Task 
Force, the complications due to hypertension are among the 
most common and most serious diseases in the U.S. Screening 
for hypertension is thus recommended for all children and 
adults.
Sensitivity Analysis
A one-way sensitivity analysis for the treatment of 
diabetes, hyperlipidemia and hypertension identified age 
and treatment costs as influential variables. The ranges 
used in the sensitivity analyses are specified in (Table 
3) .
24





Diabetes 1, 228 1 03 2,-.,
Hyperlipidemia 1638 636-2 223
Varying the age
Treating MS risk factors in younger individuals was 
found to be more effective than treating the same risk 
factors in older individuals. This is because early 
detection of disease is associated with substantial 
increases in the quality of life. Although intensive 
treatment of MS risk factors is more effective for younger 
people, it came at an increased cost to society. Treating 
MS risk factors in younger individuals saved more lives 
than it did in older individuals. These results confirm our 
assumptions that preventive treatment strategies that start
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early on in life are a more cost effective approach than 
are late treatment strategies. These data also complement 
studies that have shown that the majority of deaths below 
the age of 65 are preventable through interventions easily 
provided in a clinician's office (U.S. Preventive Services 
Task Force, 1996).
Treatment of hypertension, hyperlipidemia and diabetes 
together from age 20 resulted in 25 lives saved per year 
among blacks and 26 lives saved per year among the general 
population. The additional number of lives saved in the 
U.S. from age 20 to 70 dropped to 11.76 per year in blacks 
and to 12 per year in the general population. This was a 
drop of 53.6% in blacks and 53.8% in the general 
population.
Varying Costs
Increasing treatment costs decreased the cost 
effectiveness of treating MS risk factors. Conversely, 
reducing treatment costs resulted in a higher cost 
effectiveness. The incremental cost for the treatment of 
diabetes in blacks ranged between $9,346/QALY and 
$14,165/QALY, treatment of hypertension was between
26
$2,190/QALY and $4,582/QALY and treatment of hyperlipidemia 
between $116,159/QALY and $229,518/QALY.
The incremental cost for the treatment of diabetes in 
the general population ranged between $23,685/QALY and 
$31,513/QALY, treatment of hypertension was between 
$140/QALY and $8,880/QALY and treatment of hyperlipidemia 
between $4,783/QALY and $38,901/QALY. We did not attempt 
to do a sensitivity analysis for the treatment of all three 
risk factors because data on the appropriate limits is 
unavailable.
Discussion
Discounting is one of the prominent topics of debate 
in health economics as the idea that money today is worth 
more than money tomorrow also extends into health care 
analysis. Traditionally there have been two competing 
theories regarding the social discount rate: the social 
opportunity cost theory and the social rate of time 
preference theory (Drummond et al, 2000). While we have 
used a constant discount rate (social rate of time 
preference) of 3% in our analysis, this standard practice
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by Weinstein and Stason (1977) has been criticized by some 
who argue that it does not fairly reflect a timeless 
societal preference for health and wealth, that is, 
individuals do not discount at constant rates (Cairns and 
van der Pol, 1996; Harvey, 1994, Brouwer and van Exel,
2004). Still others argue that there are differences 
between societal time preferences and individual time 
preferences (Olsen, 1993) and that costs and effects should 
be discounted at different rates (Gold et al, 1996).
While these arguments are compelling, we decided to 
follow the recommendations of the US Public Health Service 
Panel on Cost-Effectiveness in Health and Medicine (Gold et 
al, 1996). This expert panel argued that costs and effects 
should be discounted at a rate consistent with the shadow- 
price-of-capital approach to evaluating public investments. 
Given currently available data on real economic growth and 
given corresponding estimates of the real interest rate, 
the panel agreed that a rate of 3% would most closely 
estimate the real (riskless) discount rate for CEA.
Since CEA measures technical efficiency, rather than 
allocative efficiency it cannot easily indicate whether 
something is worth doing (Boardman et al, 2001). Hadley and
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Holahan (2003) address this problem by choosing the annual 
cost it takes to treat ESRD as the de facto standard cost 
by which society in the U.S. is willing to pay for a health 
care intervention. Their assumption is based on the fact 
that MEDICARE, a federal health insurance program designed 
to provide health care for the elderly and the disabled 
also supports ESRD patients.
The incremental cost per QALY of most of the 
interventions in this study fall below the $42,400/QALY it 
takes to treat an ESRD patient. This is true for the 
treatment of hyperlipidemia, diabetes and hypertension for 
all ages in the general population and for the treatment of 
diabetes and hypertension for all ages in blacks. The 
incremental cost per QALY was below $42,400/QALY when all 
three MS risk factors were treated in blacks above 40 
years. It was also below $42,400/QALY when all three MS 
risk factors were treated in the general population above 
50. It can be hypothesized that U.S. society is willing to 
pay for these interventions.
Early treatment of hypertension among blacks proved to 
be the most cost effective option. It is clear that 
mortality from several common and serious diseases can be
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lowered through the detection and treatment of high blood 
pressure. As cited by Collins et al (1990), a reduction in 
diastolic BP by 5-6 mm Hg in hypertensive patients could 
reduce the accidence of coronary heart disease by 14% and 
incidence of strokes by 42%. Since blacks are especially 
prone to hypertension, its late treatment ultimately leads 
to massive increases in the health care costs borne by 
society.
Early treatment of hyperlipidemia in blacks proved to 
be the least cost effective option. This was because the 
high cost of aggressive treatment of hyperlipidemia did not 
result in a significant improvement in the quality of life 
among blacks. Our results complement recommendations set by 
the U.S. Preventive Task Force (1996), which found no 
sufficient benefits in routine screening of hyperlipidemia 
in children, adolescents, or young adults.
We found that at all ages and all costs in the 
general population, treatment of hypertension, 
hyperlipidemia and diabetes together was less cost 
effective than targeting a single risk factor. This is 
because the added cost in treating all three risk factors 
did not significantly improve the quality of life. In
30
general, screening for hypertension was the most cost 
effective option, followed by diabetes screening and 
hyperlipidemia screening.
The values estimated in this study compare favorably 
to federally mandated health care interventions. In a study 
that looked at the cost effectiveness of 587 public health 
care interventions in the U.S., Tengs et al (1996) found 
that the overall median intervention costs were about 
$42,000/QALY. The median medical intervention cost was 
$19,000/QALY; injury reduction $48,000/QALY; and toxin 
control $2,800,000/QALY.
Our results also compare well to cost effectiveness 
analyses carried out by Graham et al (1997) and Groeneveld 
et al (2001). Graham et al (1997) by looking at "The cost 
effectiveness of airbags by seating position," in a 
federally mandated program, demonstrated that driver side 
airbags have a cost effectiveness of $30,000/QALY while 
passenger side airbags save lives at a cost of 
$76,500/QALY. Groeneveld et al (2001) concluded that the 
incremental cost effectiveness of full Automated External 
Defibrillator deployment on commercial aircraft ranged
31
between $ 35,300 and $ 94,700 per QALY. Some major aircraft 
carriers have now deployed AED's in their aircraft.
Limitations
Although our economic analysis satisfied most of the 
criteria critical for a robust evaluation (Drummond et al, 
2000; pp 27-51), we identified significant limitations.
The unavailability of reliable literature on the 
combined costs and effects of treating MS risk factors 
proved to be a big limitation. Although some studies have 
been performed to investigate the differences in MS event 
rates among the different races and ethnicities in the 
U.S., we are to our knowledge the first to compare the cost 
effectiveness of treating MS risk factors in blacks and the 
general population. Our study would have benefited had we 
been able to access similar studies and their associated 
data.
Another limitation is that our assumptions consider 
late term treatment as no treatment at all. This is not 
the case in the model as we have incorporated the effects
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of moderate treatment into late treatment. Our decision to 
do this reflects our realization that, in reality, most at 
risk individuals do receive some sort of treatment over 
time and thus a strictly "no treatment" option is 
impractical. Accuracy in the analysis can be improved if 
late treatment is actually modeled as no treatment at all. 
This issue may be addressed by a sensitivity analysis that 
varies the costs of late treatment. Our initial study did 
not carry out this sensitivity analysis because we felt it 
would overly complicate our model.
The model assumes that patients in the early treatment 
group will follow an aggressive treatment regimen. The 
model does not allow for external factors such as non- 
compliance, discontinuation of treatment, adoption of other 
therapies or lifestyle adjustment. Lifestyle adjustments 
such as diet, physical inactivity, and nicotine and alcohol 
consumption play an important role in the manifestation of 
MS (Regenauer, 1996).
Our model does not incorporate clinical events that 
occur before diagnosis and assumes that individuals are in 
perfect health at the start of the treatment regimen. The 
model also assumes that treatment of MS begins at the onset
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of the syndrome. In practice, individuals are not in 
perfect health at the start of treatment. In addition, 
treatment can only begin after clinical diagnosis.
One weakness of the Markov Model is that it requires 
rigid assumptions such as zero memory. With zero memory the 
transition probabilities depend only on the individual's 
current health state and not on prior events (Drummond et 
al, 2000; Beck and Pauker, 1983). If the model cannot refer 
to prior events in its analysis, it cannot adequately 
incorporate the interaction of risk factors over time.
Zero memory is a severe limitation because each of the 
MS components is known to be a risk factor for other 
conditions. As cited by Reaven et al (1996) and Zavaroni 
(1999), risk factors in combination, significantly increase 
the chance of developing potentially life-threatening 
illnesses such as ESRD, MI and stroke. Furthermore, having 
one component of MS increases your chances of having other 
components of the syndrome. The more components of MS one 
exhibits the greater is ones risk of CVD. Studies have 
indicated that men with three MS risk factors are nearly 
twice as likely to have a MI or stroke and more than three 
times more likely to develop heart disease than those with
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none. Men with four or five factors face four times the 
risk of MI and stroke and more than 24 times the risk of 
diabetes (Lakka et al, 2002).
Though the model adequately represents event incidence 
and mortality as a function of age, it does not address 
event incidence as a function of gender. This is a severe 
limitation because prevalence of MS is about 57% higher in 
black women than it is in black men. More accurate results 
could be obtained from our analysis if gender was used as a 
subgroup in both blacks and the general population.
While cost benefit analysis is generally considered to 
be the preferred choice for valuing economic projects or 
policies (Boardman et al, 2001), economic evaluation in 
health care is often based on CEA criterion of dollars per 
QALY (Blomqvist, 1998). The QALY however, is not a perfect 
measure of health outcomes and has been criticized on both 
technical and ethical grounds. Scholars point out that the 
QALY is a needlessly complex approach that should be 
replaced by a more straightforward measure of 
effectiveness. Still others argue that the QALY is overly 
theoretical and should be replaced by simpler and more 
practical methods (Blomqvist, 1998; Garber and Phelps,
35
1997; Weinstein, 1995; Meltzer, 1997; Prieto and Sacristin, 
2003, Doctor et al, 2004; Moatii et al 1995). For a brief 
discussion on the QALY and its alternatives see Appendix B.
Treatment costs used in the model were derived from 
1997 dollars and adjusted for inflation to represent 2004 
dollars. Costs are then discounted at a constant rate of 3% 
per year until the patient dies. Although standard practice 
in economic analysis allows us to discount costs and 
effects alike at a constant rate of 3-5%, many have raised 
questions about this practice (Brouwer and van Exel, 2004). 
According to the National Coalition on Health Care, health 
care inflation is increasing at a rate that is five times 
the inflation rate. It follows that discounting at a 
constant rate of 3% cannot accurately estimate future 
treatment costs and effects, as it cannot adequately 
address changes in health care inflation, changes in 
treatment quality, changes in treatment standards and 
changes in technology. An alternative method to using pre­
set discount rates may be to use a more qualitative 
approach to time preference. This method should incorporate 
diminishing marginal utility for health and wealth when 
calculating time preference (Brouwer and van Exel (2004) .
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It can be argued that, with the exception of death, 
health utilities vary over time. The health utilities for 
each of the nine health states in our model are constant 
and are therefore unable to accurately measure the true and 
dynamic nature of health utilities. We used constant rates 
of health utilities rate because data on variable rates is 
unavailable.
Conclusion
Early treatment of individual MS risk factors in 
blacks and the general population saves lives in a cost 
effective manner when compared to other health care 
interventions. With the exception of targeting 
hyperlipidemia in blacks, targeting individual MS risk 
factors was found to be more cost effective than targeting 
all three risk factors (hypertension, hyperlipidemia and 
diabetes) together. Targeting hyperlipidemia was found to 
be less cost effective than treating all three risk factors 
together.
Our cost effectiveness analysis is sufficiently robust 
even when age and treatment costs are varied. With the
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exception of hyperlipidemia treatment in blacks, changes in 
age and treatment cost did not increase the cost 
effectiveness beyond $42,400/QALY when individual risk 
factors were targeted.
Although many health care studies have shown that 
racial and ethnic disparities exist, less attention has 
been given to identifying strategies to lessen these 
disparities. Our analysis while not directly applicable 
beyond the early and late treatment of MS, can guide 
similar analyses and strategies that look to address racial 
disparities in health care. The results shown in this 
study support a growing body of literature that indicates 
the cost effectiveness of providing preventative services 
to apparently healthy patients (US Preventative Services 





A person with at least three of the following 
cardiovascular risk factors is clinically diagnosed of 
having MS (NHANES ATP III):
- Abdominal obesity: waist circumference of > 102 
cm (40 inches) in men and > 88 cm (35 inches) 
in women
- Hypertriglyceridemia: >=150 mg/dL (1.69 
mmol/cm)
- Low High Density Lipoprotein (HDL) cholesterol: 
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL 
(1.29 mmol/L) in women
- High blood pressure: >= 130/85 mm Hg




Discussion on the Definition of MS
In the late 1960s, the MS was described as a "disorder 
of genetic adaptation becoming manifest following 
unrestricted food intake and/or muscular inactivity"
(Hauner, 2002). The clustering of cardiovascular risk 
factors has since been given different names including 
Insulin Resistance Syndrome, Syndrome X, Dysmetabolic 
Syndrome, Multiple Metabolic Syndrome and Plurimetabolic 
Syndrome (Isoma et al, 2001 and Meigs, 2003). More 
recently MS has been called the "deadly quartet" to 
emphasize its high artherogenic potential (Hanefeld, 
Leonhardt and Kaplan; Hauner, 2002).
In 1998 The World Health Organization (WHO), 
which many consider as the primary authority on public 
health policy, formulated a different definition of MS. 
According to the WHO consultation for the classification of 
diabetes and its complications (Alberti and Zimmet, 1998)
MS is composed of insulin resistance in combination with
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two or more of the following cardiovascular risk factors: 
hypertension, obesity, dyslipidemia and microalbuminuria.
Emphasis on diabetes as a risk factor differentiates 
the NCEP ATP III from the WHO definition of MS. While WHO 
and other studies (Lakka et al, 2002) maintain that 
diabetes is the main factor of the MS, others think it is a 
consequence of the MS (Ford et al, 2002).
Although most scholars agree that obesity is a risk 
factor for cardiovascular disease, it is still unclear 
whether this risk can best be estimated by Body Mass Index 
(BMI) or abdominal obesity (Gus et al, 2004). WHO employs 
the use of Body Mass Index (BMI) to diagnose MS, while the 
NCEP ATP III favors waist circumference or abdominal 
obesity to diagnose MS.
Lakka et al (2002) compared the accuracy of the NCEP 
ATP III and the WHO definition of MS and concluded that the 
WHO definition had a higher accuracy in predicting 
cardiovascular risk and overall mortality associated with 
MS. Despite the findings of Lakka et al (2002), we believe 
that abdominal obesity is a better indicator of 
cardiovascular risk than is BMI.
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Our belief is supported by an extensive study showing 
the prevalence of MS in the U.S. (Ford et al, 2002). Our 
belief is also supported by Gus et al (2004) who conclude 
that the risk of hypertension may be better identified by 
obesity defined by higher waist circumference than higher 
BMI. For these reasons, we adopt the NCEP ATP III 
definition of MS.
Still others feel that neither BMI nor waist 
circumference is particularly useful in diagnosing MS 
(Schubert, 2004). Instead, a high triglyceride level has 
been cited as a more precise predictor of MS and CVD, 
especially in cases when an individual may appear non- 
symptomatic or in cases where there is variation in body 
shape due to ethnicity (He et al, 2001) .
42
Quality Adjusted Life Years
A QALY is a health index that estimates the quantity 
and quality of life generated by health care interventions. 
QALYs place weight on the time spent in different health 
states such that a year of perfect health is assigned a 
value of 1 and death is assigned a value of 0. Some health 
states are considered worse than death and are assigned 
negative scores (Thompson (2003).
Weinstein and Stason (1977) popularized the term QALY. 
QALYs are also referred to as Years of Healthy Life (YHL), 
Health Adjusted Person Years (HAPY), Health Adjusted Life 
Expectancy (HALE) (Drummond et al, 2000) and Life-Year 
Saved (LYS). Several other alternatives to QALYs exist. 
These include Health Year Equivalents (HYE) and Saved- 
Young-Life Equivalents (SAVE).
While the HYE has been proposed as a theoretically 
superior alternative to the QALY albeit more complex to 
execute, the SAVE has been proposed as a more socially 
sensitive alternative because it reflects a societal
Appendix C
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perspective to health utility. QALYs are accused of not 
measuring social value because preferences and weights are 
based on individualistic perspective rather than a societal 
perspective (Drummond et al, 2000; Mehrez and Gafni, 1992 
and Nord et al, 1993). Since it is society that ultimately 
bears the cost of health care, it would seem more 




When calculating health utilities under the standard 
gamble approach (von Neumann and Morgenstern, 1953), an 
individual is presented with two choices: (1) the certainty
of survival for a specific period of time in a particular 
state of health and (2) the gamble of survival for the same 
period of time without disability on one hand and with 
immediate death on the other. The chance of survival 
without disability, as opposed to the chance of death is 
varied until the individual is indifferent between 
certainty and gambling. This probability then estimates the 
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between $ 35,300 and $ 94,700 per QALY. Some major aircraft 
carriers have now deployed AED's in their aircraft.
Limitations
Although our economic analysis satisfied most of the 
criteria critical for a robust evaluation (Drummond et al, 
2000; pp 27-51) , we identified significant limitations.
The unavailability of reliable literature on the 
combined costs and effects of treating MS risk factors 
proved to be a big limitation. Although some studies have 
been performed to investigate the differences in MS event 
rates among the different races and ethnicities in the 
U.S., we are to our knowledge the first to compare the cost 
effectiveness of treating MS risk factors in blacks and the 
general population. Our study would have benefited had we 
been able to access similar studies and their associated 
data.
Another limitation is that our assumptions consider 
late term treatment as no treatment at all. This is not 
the case in the model as we have incorporated the effects
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of moderate treatment into late treatment. Our decision to 
do this reflects our realization that, in reality, most at 
risk individuals do receive some sort of treatment over 
time and thus a strictly "no treatment" option is 
impractical. Accuracy in the analysis can be improved if 
late treatment is actually modeled as no treatment at all. 
This issue may be addressed by a sensitivity analysis that 
varies the costs of late treatment. Our initial study did 
not carry out this sensitivity analysis because we felt it 
would overly complicate our model.
The model assumes that patients in the early treatment 
group will follow an aggressive treatment regimen. The 
model does not allow for external factors such as non- 
compliance, discontinuation of treatment, adoption of other 
therapies or lifestyle adjustment. Lifestyle adjustments 
such as diet, physical inactivity, and nicotine and alcohol 
consumption play an important role in the manifestation of 
MS (Regenauer, 1996).
Our model does not incorporate clinical events that 
occur before diagnosis and assumes that individuals are in 
perfect health at the start of the treatment regimen. The 
model also assumes that treatment of MS begins at the onset
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of the syndrome. In practice, individuals are not in 
perfect health at the start of treatment. In addition, 
treatment can only begin after clinical diagnosis.
One weakness of the Markov Model is that it requires 
rigid assumptions such as zero memory. With zero memory the 
transition probabilities depend only on the individual's 
current health state and not on prior events (Drummond et 
al, 2000; Beck and Pauker, 1983). If the model cannot refer 
to prior events in its analysis, it cannot adequately 
incorporate the interaction of risk factors over time.
Zero memory is a severe limitation because each of the 
MS components is known to be a risk factor for other 
conditions. As cited by Reaven et al (1996) and Zavaroni 
(1999), risk factors in combination, significantly increase 
the chance of developing potentially life-threatening 
illnesses such as ESRD, MI and stroke. Furthermore, having 
one component of MS increases your chances of having other 
components of the syndrome. The more components of MS one 
exhibits the greater is ones risk of CVD. Studies have 
indicated that men with three MS risk factors are nearly 
twice as likely to have a MI or stroke and more than three 
times more likely to develop heart disease than those with
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none. Men with four or five factors face four times the 
risk of MI and stroke and more than 24 times the risk of 
diabetes (Lakka et al, 2002).
Though the model adequately represents event incidence 
and mortality as a function of age, it does not address 
event incidence as a function of gender. This is a severe 
limitation because prevalence of MS is about 57% higher in 
black women than it is in black men. More accurate results 
could be obtained from our analysis if gender was used as a 
subgroup in both blacks and the general population.
While cost benefit analysis is generally considered to 
be the preferred choice for valuing economic projects or 
policies (Boardman et al, 2001), economic evaluation in 
health care is often based on CEA criterion of dollars per 
QALY (Blomqvist, 1998). The QALY however, is not a perfect 
measure of health outcomes and has been criticized on both 
technical and ethical grounds. Scholars point out that the 
QALY is a needlessly complex approach that should be 
replaced by a more straightforward measure of 
effectiveness. Still others argue that the QALY is overly 
theoretical and should be replaced by simpler and more 
practical methods (Blomqvist, 1998; Garber and Phelps,
35
1997; Weinstein, 1995; Meltzer, 1997; Prieto and Sacristin, 
2003, Doctor et al, 2004; Moatii et al 1995). For a brief 
discussion on the QALY and its alternatives see Appendix B.
Treatment costs used in the model were derived from 
1997 dollars and adjusted for inflation to represent 2004 
dollars. Costs are then discounted at a constant rate of 3% 
per year until the patient dies. Although standard practice 
in economic analysis allows us to discount costs and 
effects alike at a constant rate of 3-5%, many have raised 
questions about this practice (Brouwer and van Exel, 2004). 
According to the National Coalition on Health Care, health 
care inflation is increasing at a rate that is five times 
the inflation rate. It follows that discounting at a 
constant rate of 3% cannot accurately estimate future 
treatment costs and effects, as it cannot adequately 
address changes in health care inflation, changes in 
treatment quality, changes in treatment standards and 
changes in technology. An alternative method to using pre­
set discount rates may be to use a more qualitative 
approach to time preference. This method should incorporate 
diminishing marginal utility for health and wealth when 
calculating time preference (Brouwer and van Exel (2004).
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It can be argued that, with the exception of death, 
health utilities vary over time. The health utilities for 
each of the nine health states in our model are constant 
and are therefore unable to accurately measure the true and 
dynamic nature of health utilities. We used constant rates 
of health utilities rate because data on variable rates is 
unavailable.
Conclusion
Early treatment of individual MS risk factors in 
blacks and the general population saves lives in a cost 
effective manner when compared to other health care 
interventions. With the exception of targeting 
hyperlipidemia in blacks, targeting individual MS risk 
factors was found to be more cost effective than targeting 
all three risk factors (hypertension, hyperlipidemia and 
diabetes) together. Targeting hyperlipidemia was found to 
be less cost effective than treating all three risk factors 
together.
Our cost effectiveness analysis is sufficiently robust 
even when age and treatment costs are varied. With the
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exception of hyperlipidemia treatment in blacks, changes in 
age and treatment cost did not increase the cost 
effectiveness beyond $42,400/QALY when individual risk 
factors were targeted.
Although many health care studies have shown that 
racial and ethnic disparities exist, less attention has 
been given to identifying strategies to lessen these 
disparities. Our analysis while not directly applicable 
beyond the early and late treatment of MS, can guide 
similar analyses and strategies that look to address racial 
disparities in health care. The results shown in this 
study support a growing body of literature that indicates 
the cost effectiveness of providing preventative services 
to apparently healthy patients (US Preventative Services 





A person with at least three of the following 
cardiovascular risk factors is clinically diagnosed of 
having MS (NHANES ATP III):
- Abdominal obesity: waist circumference of > 102 
cm (40 inches) in men and > 88 cm (35 inches) 
in women
- Hypertriglyceridemia: >=150 mg/dL (1.69 
mmol/cm)
- Low High Density Lipoprotein (HDL) cholesterol: 
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL 
(1.29 mmol/L) in women
- High blood pressure: >= 130/85 mm Hg




Discussion on the Definition of MS
In the late 1960s, the MS was described as a "disorder 
of genetic adaptation becoming manifest following 
unrestricted food intake and/or muscular inactivity"
(Hauner, 2002). The clustering of cardiovascular risk 
factors has since been given different names including 
Insulin Resistance Syndrome, Syndrome X, Dysmetabolic 
Syndrome, Multiple Metabolic Syndrome and Plurimetabolic 
Syndrome (Isoma et al, 2 001 and Meigs, 2 003) . More 
recently MS has been called the "deadly quartet" to 
emphasize its high artherogenic potential (Hanefeld, 
Leonhardt and Kaplan; Hauner, 2002).
In 1998 The World Health Organization (WHO), 
which many consider as the primary authority on public 
health policy, formulated a different definition of MS. 
According to the WHO consultation for the classification of 
diabetes and its complications (Alberti and Zimmet, 1998)
MS is composed of insulin resistance in combination with
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two or more of the following cardiovascular risk factors: 
hypertension, obesity, dyslipidemia and microalbuminuria.
Emphasis on diabetes as a risk factor differentiates 
the NCEP ATP III from the WHO definition of MS. While WHO 
and other studies (Lakka et al, 2002) maintain that 
diabetes is the main factor of the MS, others think it is a 
consequence of the MS (Ford et al, 2002).
Although most scholars agree that obesity is a risk 
factor for cardiovascular disease, it is still unclear 
whether this risk can best be estimated by Body Mass Index 
(BMI) or abdominal obesity (Gus et al, 2004). WHO employs 
the use of Body Mass Index (BMI) to diagnose MS, while the 
NCEP ATP III favors waist circumference or abdominal 
obesity to diagnose MS.
Lakka et al (2002) compared the accuracy of the NCEP 
ATP III and the WHO definition of MS and concluded that the 
WHO definition had a higher accuracy in predicting 
cardiovascular risk and overall mortality associated with 
MS. Despite the findings of Lakka et al (2002), we believe 
that abdominal obesity is a better indicator of 
cardiovascular risk than is BMI.
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Our belief is supported by an extensive study showing 
the prevalence of MS in the U.S. (Ford et al, 2002). Our 
belief is also supported by Gus et al (2004) who conclude 
that the risk of hypertension may be better identified by 
obesity defined by higher waist circumference than higher 
BMI. For these reasons, we adopt the NCEP ATP III 
definition of MS.
Still others feel that neither BMI nor waist 
circumference is particularly useful in diagnosing MS 
(Schubert, 2004) . Instead, a high triglyceride level has 
been cited as a more precise predictor of MS and CVD, 
especially in cases when an individual may appear non- 
symptomatic or in cases where there is variation in body 
shape due to ethnicity (He et al, 2001).
42
Quality Adjusted Life Years
A QALY is a health index that estimates the quantity 
and quality of life generated by health care interventions. 
QALYs place weight on the time spent in different health 
states such that a year of perfect health is assigned a 
value of 1 and death is assigned a value of 0. Some health 
states are considered worse than death and are assigned 
negative scores (Thompson (2003).
Weinstein and Stason (1977) popularized the term QALY. 
QALYs are also referred to as Years of Healthy Life (YHL), 
Health Adjusted Person Years (HAPY), Health Adjusted Life 
Expectancy (HALE) (Drummond et al, 2000) and Life-Year 
Saved (LYS). Several other alternatives to QALYs exist. 
These include Health Year Equivalents (HYE) and Saved- 
Young-Life Equivalents (SAVE).
While the HYE has been proposed as a theoretically 
superior alternative to the QALY albeit more complex to 
execute, the SAVE has been proposed as a more socially 
sensitive alternative because it reflects a societal
Appendix C
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perspective to health utility. QALYs are accused of not 
measuring social value because preferences and weights are 
based on individualistic perspective rather than a societal 
perspective (Drummond et al, 2000; Mehrez and Gafni, 1992 
and Nord et al, 1993). Since it is society that ultimately 
bears the cost of health care, it would seem more 




When calculating health utilities under the standard 
gamble approach (von Neumann and Morgenstern, 1953), an 
individual is presented with two choices: (1) the certainty
of survival for a specific period of time in a particular 
state of health and (2) the gamble of survival for the same 
period of time without disability on one hand and with 
immediate death on the other. The chance of survival 
without disability, as opposed to the chance of death is 
varied until the individual is indifferent between 
certainty and gambling. This probability then estimates the 
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